Drugs for treating acute migraine headaches in children and adolescents

2005 ◽  
Author(s):  
Lori Billinghurst ◽  
Lawrence Richer ◽  
Kelly F Russell ◽  
Ben Vandermeer ◽  
Ellen Crumley ◽  
...  
2013 ◽  
Author(s):  
Sheena Derry ◽  
R Andrew Moore ◽  
Henry J McQuay

Pain Practice ◽  
2014 ◽  
Vol 15 (8) ◽  
pp. 701-705 ◽  
Author(s):  
Hossein Moshtaghion ◽  
Najmeh Heiranizadeh ◽  
Abolghasem Rahimdel ◽  
Alireza Esmaeili ◽  
Hamidreza Hashemian ◽  
...  

2008 ◽  
Vol 13 (1) ◽  
pp. 17-24 ◽  
Author(s):  
Michelle Brenner ◽  
Donald Lewis

Effective management of migraine headache in children and adolescents requires a balanced approach with an individually tailored regimen targeted to treat an acute attack at its onset, blended with bio-behavioral measures, and, in about 1/3 of patients, daily preventive medicines. The key first step is to assess the disability imposed by the recurrent headache pattern, the headache “burden.” Once the burden is established decisions can be made toward selecting the most appropriate course of action. All patients will benefit from some basic bio-behavioral suggestions such as regular sleep, exercise, and eating schedule, moderation of caffeine, and identification of triggers. In addition, all patients should have a readily available analgesic to be used at the onset of a migraine attack. A subset of migraineurs will have sufficient headache burden to necessitate use of daily preventative medications. Unfortunately, there is limited controlled data to provide a comprehensive, evidence-based guideline, however, the most rigorously studied agents for acute treatment are ibuprofen, acetaminophen, and “triptan” nasal spray forms of sumatriptan and zolmitriptan; all of these have shown safety and efficacy in controlled trials. For preventive treatment, flunarizine, not available in the U.S., is the only agent that has demonstrated efficacy in placebo controlled trials, but encouraging data is emerging regarding the use of several antiepileptic agents such as topiramate, disodium valproate, and levetiracetam, as well as the antihistamine cyproheptadine and the antidepressant amitriptyline.


PEDIATRICS ◽  
1995 ◽  
Vol 95 (5) ◽  
pp. 789-790
Author(s):  

Mitral valve prolapse (MVP) is generally a benign condition characterized by the protrusion of the mitral valve leaflets into the left atrium during systole. The prevalence of MVP in individuals under the age of 18 years is estimated to be 5% but is higher in those with Marfan's syndrome and other collagen vascular disorders.1 A midsystolic nonejection click with or without a late systolic murmur is the auscultatory hallmark of this syndrome. The diagnosis of MVP in children and adolescents should be based primarily on auscultatory findings and not on minor echocardiographic findings.1 The prognosis in children and adolescents with isolated MVP appears to be excellent and complications are rare. In 553 children, aged 15 days to 18 years, who were involved in studies with a follow-up period of 6 to 9 years, the following were reported: subacute bacterial endocarditis (one case), cerebral vascular accidents (two cases), migraine headaches (four cases), and chest pain (12 cases).2,3 Only four cases of sudden death have been reported in patients younger than 20 years of age.1-4 In a study of 103 patients with MVP, 16% were found to have premature ventricular beats during exercise electrocardiography (ECG) (exercise test).3 Thirty-eight percent were found to have premature ventricular contractions (PVCs) on 24-hour ECG (Holter) monitoring. This study, however, does not report the true prevalence of dysrhythmias because all these subjects had been referred to a pediatric cardiologist for evaluation. It is likely that these reported numbers are high because asymptomatic patients are less often referred.


2020 ◽  
Vol 10 (5) ◽  
pp. 401-407 ◽  
Author(s):  
Abbey Masonbrink ◽  
Troy Richardson ◽  
Delwyn Catley ◽  
Melissa K. Miller ◽  
Matt Hall ◽  
...  

2010 ◽  
Author(s):  
Rebecca Ling ◽  
Sheena Derry ◽  
R Andrew Moore ◽  
Philip J Wiffen

2014 ◽  
Vol 49 (2) ◽  
pp. 233-240 ◽  
Author(s):  
Michael C. Thomas ◽  
Megan E. Musselman ◽  
Justin Shewmaker

Sign in / Sign up

Export Citation Format

Share Document